Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2

Status

Completed 5Recruiting 2

Sponsor Class

INDUSTRY 7OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 43Thoracic 20Genitourinary 8Tumor-Agnostic 7Other solid neoplasm 7Breast 5Sarcoma 3Dermatologic 3Lymphoid 2Gynecologic 2Head & Neck 1CNS 1

Conditions

Neoplasms 5Adenocarcinoma 2Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Ramucirumab × Tumor-Agnostic × Clear all
NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT01285037 2018-02-20

A Study of LY2801653 in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
190 enrolled
Tumor-Agnostic

Neoplasms

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Eli Lilly and Company

Phase 2 Completed
68 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01253525 2014-06-18

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Eli Lilly and Company

Phase 1 Completed
6 enrolled 18 charts
Tumor-Agnostic

Adenocarcinoma

NCT00786383 2013-08-19

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

Eli Lilly and Company

Phase 1 Completed
25 enrolled
Tumor-Agnostic

Neoplasms

NCT00793975 2013-08-19

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Eli Lilly and Company

Phase 1 Completed
37 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡